Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.46 |
| ▸ | MME | P08473 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL909961 | 1.00 | ITGB3 (0.52) | ITGB3ITGA2BITGB1ITGA4LMNA | |
| SCHEMBL7495527 | 0.90 | TSHR (0.49) | LMNACYP1A2CYP3A4CYP2C9TSHR | |
| SCHEMBL2252892 | 0.88 | FOLH1 (0.56) | ITGB3ITGA2BITGB1ITGA4LMNA | |
| SCHEMBL2252894 | 0.88 | FOLH1 (0.56) | ITGB3ITGA2BITGB1ITGA4LMNA | |
| SCHEMBL5085763 | 0.88 | ITGB1 (0.56) | ITGB3ITGA2BITGB1ITGA4ACE | |
| SCHEMBL5086266 | 0.88 | ITGB1 (0.56) | ITGB3ITGA2BITGB1ITGA4ACE | |
| SCHEMBL844471 | 0.88 | ITGB3 (0.58) | ITGB3ITGA2BITGB1ITGA4ACE | |
| SCHEMBL7758997 | 0.88 | ITGB3 (0.58) | ITGB3ITGA2BITGB1ITGA4ACE | |
| SCHEMBL2185240 | 0.88 | ITGB3 (0.58) | ITGB3ITGA2BITGB1ITGA4ACE | |
| SCHEMBL8023605 | 0.87 | ITGB1 (0.52) | ITGB3ITGA2BITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0843672-B1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-13 | — | — | EP | claimed |
| EP-0843673-B1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-11-07 | — | — | EP | claimed |
| US-6303791-B1 | REACTING METHYL 4-NITRO-(L)-PHENYLALANINATE HYDROCHLORIDE WITH N-BUTYL CHLOROFORMATE TO FORM CARBAMATE, REDUCING NITRO GROUP TO AMINE AND ESTER GROUP TO ALCOHOL, CYCLIZING, FORMING DIAZONIUM SALT, REDUCING, PERFORMING FISCHER REACTION | ZENECA LIMITED (GB) | 2001-10-16 | — | — | US | claimed |
| US-6084103-A | FORMING A CARBAMATE FROM METHYL 4-NITRO-(L)-PHENYLALANINATE HYDROCHLORIDE; REDUCING THE NITRO AND ESTER GROUPS; RING CLOSURE FREE OF PHOSGENE; FORMING A DIAZONIUM SALT WITHOUT USING TIN CHLORIDE; FISCHER REACTION; MIGRAINES; 5HT1-AGONIST | ZENECA LIMITED (GB) | 2000-07-04 | — | — | US | claimed |
| US-20060264643-A1 | One Pot Synthesis of 2-Oxazolidinone Derivatives | ASTRAZENECA UK LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1227095-B1 | A process for the purification of (S)-4-((3-(dimethylamino)ethyl)-1H-indol-5yl)-methyl)-2-oxazolidinone | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20050187274-A1 | One pot synthesis of 2-oxazolidinone derivatives | PATEL RAJNIKANT (GB) | 2005-08-25 | — | — | US | disclosed |
| US-6909005-B1 | One post synthesis of 2-oxazolidinone derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-06-21 | — | — | US | disclosed |
| WO-2004063175-A1 | A NOVEL AND AN IMPROVED PROCESS FOR THE PREPARATION OF (S)-4-(4-AMINOBENZYL)-2- OXAZOLIDINONE | NATCO PHARMA LIMITED (IN) | 2004-07-29 | — | — | WO | disclosed |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| EP-1290011-A1 | MELPHALAN DERIVATIVES AND THEIR USE AS CANCER CHEMOTHERAPEUTIC DRUGS | Oncopeptides AB (SE) | 2003-03-12 | — | — | EP | disclosed |
| EP-0843672-B1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-13 | — | — | EP | disclosed |
| EP-0843673-B1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| US-6303791-B1 | REACTING METHYL 4-NITRO-(L)-PHENYLALANINATE HYDROCHLORIDE WITH N-BUTYL CHLOROFORMATE TO FORM CARBAMATE, REDUCING NITRO GROUP TO AMINE AND ESTER GROUP TO ALCOHOL, CYCLIZING, FORMING DIAZONIUM SALT, REDUCING, PERFORMING FISCHER REACTION | ZENECA LIMITED (GB) | 2001-10-16 | — | — | US | disclosed |
| US-6160123-A | One pot synthesis of 2-oxazolidinone derivatives | ZENECA, LTD. (GB) | 2000-12-12 | — | — | US | disclosed |
| US-6084103-A | FORMING A CARBAMATE FROM METHYL 4-NITRO-(L)-PHENYLALANINATE HYDROCHLORIDE; REDUCING THE NITRO AND ESTER GROUPS; RING CLOSURE FREE OF PHOSGENE; FORMING A DIAZONIUM SALT WITHOUT USING TIN CHLORIDE; FISCHER REACTION; MIGRAINES; 5HT1-AGONIST | ZENECA LIMITED (GB) | 2000-07-04 | — | — | US | disclosed |
| EP-0843673-A1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1998-05-27 | — | — | EP | disclosed |
| EP-0843672-A1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1998-05-27 | — | — | EP | disclosed |
| WO-1997006162-A1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-02-20 | — | — | WO | disclosed |
| WO-1997006163-A1 | ONE POT SYNTHESIS OF 2-OXAZOLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264643-A1 | One Pot Synthesis of 2-Oxazolidinone Derivatives | AZI2, INTS6, NISCH | ITGB3 2513/4885ITGA2B 2137/4885ITGB1 2227/4885 |
| US-20050187274-A1 | One pot synthesis of 2-oxazolidinone derivatives | AZI2, INTS6, NISCH | ITGB3 2474/4885ITGA2B 2119/4885ITGB1 2197/4885 |
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | ITGB3 10/4885ITGA2B 55/4885ITGB1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.